Search Results

You are looking at 181 - 190 of 441 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Eric Jonasch

is partial or radical nephrectomy or, in select patients, active surveillance. Further treatment is typically not recommended. “Following nephrectomy, adjuvant therapy for RCC has been an exercise in frustration,” he pointed out. Recent studies

Full access

Christopher G. Willett

. Locoregional Rectal Cancer: What's New “The rectal cancer guidelines have been completely reworked to include the idea of mirroring the adjuvant therapies that we use in colon cancer,” said Dr. Grothey. “In the past few years, every time our committee looked

Full access

Ingrid A. Mayer

by progressive disease within 6 months of starting treatment with endocrine therapy in the metastatic setting, or the development of metastatic recurrence during or shortly after completing adjuvant therapy. Secondary (acquired) resistance is

Full access

Eric Jonasch

not support the use of adjuvant therapy for RCC in 2015. With the advent of various antiangiogenic agents and mTOR inhibitors, investigators have moved past the cytokine therapy era, he noted. In the upcoming years, Dr. Jonasch predicted, the next wave

Full access

Kari E. Hacker, Shitanshu Uppal, and Carolyn Johnston

patients with pathology upgraded to carcinoma were included in analyses. 53 Finally, some gynecologic oncologists recommend completion of surgery after childbearing, because most recurrences are in the contralateral ovary. 56 Adjuvant therapy is

Full access

J. Sybil Biermann

extremity: a review of 349 cases from a single institution . Cancer Treat Rev 2010 ; 36 : 1 – 7 . 2. Becker WT Dohle J Bernd L . Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy . J

Full access

Elizabeth J. Cathcart-Rake and Kathryn J. Ruddy

: Lessons From Medicare Part D,” in this issue of JNCCN (page 1509 ) adds to the current literature on cancer care disparities in that it reveals how state-level variability in Medicare Part D benefits influence adjuvant therapy prescriptions

Full access

Robert Torrey, Philippe E. Spiess, Sumanta K. Pal, and David Josephson

method of operation. However, this information is important to review postoperatively because it may better identify patients with aggressive pathologic features potentially suitable for adjuvant therapy clinical trials. The Role of Lymphadenectomy

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, and Jue Wang

Elson P Propert K . Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high-risk renal cell carcinoma [abstract] . Proc Am Soc Clin Oncol 1996 ; 15 : Abstract 253 . 19 Kavolius JP

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, and Jue Wang

2002 ; 9 : 277 – 283 . 22 Motzer RJ Sheinfeld J Mazumdar M . Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ-cell tumors . Classic Papers and Current Comments: Highlights of Genitourinary Cancer Research